Zedira is a privately held clinical stage biotech company based in Darmstadt, Germany.

The Company focuses on disorders linked to the enzyme family of transglutaminases.

Zedira’s business model is focused on the development of small molecule drug candidates for early licensing.
Zedira’s drug candidate for celiac disease therapy, tissue transglutaminase (TG2) blocker ZED1227 is currently tested in phase 2a clinical trials.

ZED1227 is licensed to Dr. Falk Pharma for Europe and four other countries. Dr. Falk Pharma took over responsibility for preclinical and clinical development as well as for approval and marketing of the drug.

Current internal development work focuses on second generation TG2 inhibitors optimized for systemic indications. Zedira medicinal chemists discovered a novel class of reversible-acting blockers combining high potency along with excellent selectivity. Zedira taps the potential of these oral bio available compounds to address systemic indications, especially fibrotic disorders (e.g. diabetic nephropathy).

Further, Zedira developed coagulation FXIIIa blockers (F13a, plasma transglutaminase) for safe anticoagulation (thromboprophylaxis). This unique and promising approach has the potential of a significant reduction in the life-threatening tendency to bleeding as provoked by current drugs.

In a rabbit animal model, Zedira already showed the proof of principle of “safe” anticoagulation therapy by inhibition of Factor XIIIa.

The Company’s management is open to considering investment by private individuals and institutions.
Please do not hesitate to contact us if you are interested in an attractive opportunity.

Zedira’s managing partners, Dr. Martin Hils and Dr. Ralf Pasternack, will be pleased to be at your disposal:

Phone:		+49 6151 3251-00 or
E-mail:		contact@zedira.com